Scienmag

MARCH 25, 2021

The largest study of its kind to date also found benefit for lactating women BOSTON – In the largest study of its kind to date, researchers at Massachusetts General Hospital, Brigham and Women’s Hospital and the Ragon Institute of MGH, MIT and Harvard have found the new mRNA COVID-19 vaccines to be highly effective in […].

Immune Response 69

Immune Response Vaccination Vaccine Antibody 69

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

The Pharma Data

DECEMBER 18, 2020

ACAAI: Reaction to COVID-19 Vaccine Unlikely for Those With Common Allergies. The ACAAI COVID-19 Vaccine Task Force issued the guidance related to the risk for an allergic reaction with the Pfizer-BioNTech COVID-19 vaccine that was given emergency use authorization by the U.S. FRIDAY, Dec. FRIDAY, Dec. © 2020 HealthDay.

Allergies 52

Allergies Vaccination Vaccine Immune Response 52

Scienmag

DECEMBER 9, 2020

Phase 2 trials in 1,200 adults, young children, and infants suggest new poliovirus vaccine may have the potential to overcome outbreaks caused by a mutated polio strain linked to the oral vaccine that typically circulates in areas of low immunisation coverage, and poses one of biggest barriers to eradication.

Immune Response 75

Immune Response Vaccination Vaccine Scientist 75

XTalks

AUGUST 16, 2021

The US Food and Drug Administration (FDA) has amended its emergency use authorizations (EUA) for both the Pfizer and Moderna COVID-19 vaccines to incorporate a third dose for immunocompromised individuals. A small study from John Hopkins University has shown that a third dose of a COVID-19 vaccine could indeed help immunocompromised patients.

Vaccination 104

Vaccination Vaccine Antibody Immune Response 104

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Scienmag

NOVEMBER 18, 2020

Older adults are at a disproportionate risk of severe COVID-19 disease, so it is essential that any vaccine adopted for use against SARS-CoV-2 is effective in this group Peer-reviewed / Randomised Controlled Trial / People **There will be a UK Science Media Centre briefing at 10.15am UK time on Thursday 19th November about this study. […].

Immune Response 74

Immune Response Vaccination Vaccine Trials 74

XTalks

AUGUST 13, 2020

As the rush for a COVID-19 vaccine continues, healthcare services company Kaiser Permanente has joined in on the clinical testing of Pfizer Inc. and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

Scienmag

NOVEMBER 17, 2020

Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate (CoronaVac) involved more than 700 healthy volunteers aged 18-59 years recruited in China between 16 April and 5 May 2020 Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate (CoronaVac) involved more than 700 healthy volunteers aged (..)

Immune Response 70

Immune Response Vaccination Vaccine Trials 70

Scienmag

JULY 7, 2021

Researchers have produced vaccine-like immune responses to a dangerous bacterium by colonizing 26 healthy volunteers with a related, but harmless, commensal bacterial species.

Bacteria 75

Bacteria Bacterium Immune Response Vaccination 75

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. The UK pharma said that the trial will recruit up to 30,000 adults aged 18 years or over to assess the safety, efficacy and immune response.

Vaccination 69

Vaccination Vaccine Trials Immune Response 69

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. By ordering human cells to make the protein, ZyCoV-D could cause an immune response against the coronavirus.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. TUESDAY, Dec. © 2020 HealthDay. All rights reserved. Source link.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

The Pharma Data

JANUARY 9, 2021

9, 2021 — A task force of allergists and immunologists recommends those administering the COVID-19 vaccine ask patients some key questions beforehand. If the answer is yes, the individual should be referred to a board-certified allergist for evaluation before getting the COVID-19 vaccination, ACAAI said in a news release.

Vaccination 52

Vaccination Vaccine Allergies Immune Response 52

Pfizer

JULY 19, 2022

1 Adapted Bivalent Vaccine Candidate. 1 Adapted Bivalent Vaccine Candidate. NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted bivalent COVID-19 vaccine candidate, based on the BA.1 Tue, 07/19/2022 - 11:22. Booster Series.

Vaccination 100

Vaccination Vaccine Medicine Clinical Trials 100

Scienmag

MARCH 19, 2021

Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds. MIT researchers have now developed a vaccination strategy that can create an army of T cells that are […].

Vaccination 48

Vaccination Vaccine Immune Response Development 48

Scienmag

OCTOBER 15, 2020

Phase 1/2 randomised controlled trial of an inactivated SARS-CoV-2 vaccine candidate was carried out in China between 29 April and 30 July 2020 and involved more than 600 healthy volunteers.

Immune Response 52

Immune Response Vaccination Vaccine Clinical Trials 52

Scienmag

FEBRUARY 19, 2021

Preclinical tests at UAB last year showed potent systemic and mucosal immune responses in mice after a single intranasal dose. The vaccine candidate was developed by Maryland-based Altimmune Inc. vaccine candidate that was tested preclinically at the University of Alabama at Birmingham last year is expected to […].

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Scienmag

NOVEMBER 6, 2020

New study demonstrates candidate’s potential to generate antibodies, limit viral shedding Credit: Craig Chandler, University of Nebraska-Lincoln A genetically edited form of a herpes simplex virus — rewired to keep it from taking refuge in the nervous system and eluding an immune response — has outperformed a leading vaccine candidate (..)

Vaccination 49

Vaccination Vaccine Immune Response Genetics 49

Pfizer

JULY 8, 2022

FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age. The vaccine was previously made available to this age group in the U.S. Fri, 07/08/2022 - 11:48. Pfizer and BioNTech Announce U.S.

FDA Approval 102

FDA Approval Vaccination Vaccine Clinical Trials 102

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada. Conor Kavanagh. Source link.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Pfizer

JULY 8, 2022

Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY®. Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY®. Pfizer-BioNTech COVID-19 Vaccine is FDA authorized to provide: Primary Series.

Vaccination 81

Vaccination Vaccine Clinical Trials Clinical Trials 81

Scienmag

JANUARY 13, 2021

Previous research suggests stress, depression, inactivity could interfere with immune response COLUMBUS, Ohio – While we wait for our turn to get vaccinated against SARS-CoV-2, we could – and probably should – use the time to make sure we bring our healthiest emotional and physical selves to the treatment, a new review of previous (..)

Vaccination 41

Vaccination Vaccine Immune Response Research 41

The Pharma Data

APRIL 3, 2021

Johnson & Johnson (the Company) has begun vaccinating adolescent participants in the ongoing Phase 2a clinical trial for its COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen’s COVID-19 Vaccine Candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. It is now following up with data from a small group of older adults, and they look positive.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% “Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. Glenn, M.D.,

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. This new study will complement Mymetics’ other preclinical Covid-19 studies that are ongoing at Baylor College of Medicine in Texas USA and the Helmholtz Center of Infection Research in Germany.

Vaccination 40

Vaccination Vaccine Containment Development 40

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” . PLYMOUTH MEETING, Pa. , mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Scienmag

APRIL 19, 2021

A study of immune cells circulating in the blood hints the gut’s immune response to COVID-19 infection may not provide sufficient whole-body immunity from the virus Our guts may not provide long-lasting systemic immunity from COVID-19, which is where immune cells circulate through the body to provide protection to other organs, finds a new study (..)

Immune Response 74

Immune Response Allergies Vaccination Vaccine 74

Scienmag

SEPTEMBER 15, 2020

Scientists will study how SARS-CoV-19 hijacks the immune system and creates a ‘cytokine storm’ Credit: Sanford Burnham Prebys Medical Discovery Institute.

Immune Response 60

Immune Response Scientist Drugs Allergies 60

Scienmag

FEBRUARY 18, 2021

Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults.

Antibody 74

Antibody Immune Response Development Research 74

Scienmag

OCTOBER 1, 2020

Whether flu or coronavirus, it can take several days for the body to ramp up an effective response to a viral infection.

Immune Response 40

Immune Response Research Allergies Vaccination 40

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44. Thursday, November 03, 2022 - 06:45am. Ugur Sahin, M.D.,

Vaccination 85

Vaccination Vaccine Clinical Trials Clinical Trials 85

XTalks

MAY 17, 2024

Every year on May 18th, the global community commemorates World AIDS Vaccine Day, also known as HIV Vaccine Awareness Day. Led by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), World AIDS Vaccine Day emphasizes the importance of awareness and education in the fight against HIV/AIDS.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

pharmaphorum

FEBRUARY 28, 2021

The FDA has approved emergency use of a third COVID-19 vaccine from Johnson & Johnson’s Janssen Biotech unit, the day after an advisory committee concluded it was safe and effective. Today, FDA issued an emergency use authorization (EUA) for the third vaccine for the prevention of #COVID19 caused by SARS-CoV-2. Janssen’s Ad26.COV2.S

Vaccination 59

Vaccination Vaccine Immune Response Protein 59